- Primary prevention of cervical cancer: resource-stratified leadership of the American Society of Clinical Oncology
Primary prevention of cervical cancer: resource-stratified leadership of the American Society of Clinical Oncology
HEALTH OF WOMAN. 2017.7(123):143–157
Abridged version. Adapted – S.A. Shurpyak
1. Forman D, de Martel C, Lacey CJ et al. 2012. Global burden of human papillomavirus and related diseases. Vaccine 30:F12-F23 (suppl 5).
2. Castellsague X, Alemany L, Quer M et al. 2016. HPV involvement in head and neck cancers. Comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 108:djv403. https://doi.org/10.1093/jnci/djv403; PMid:26823521
3. International Agency for Research on Cancer: GLOBOCAN 2012 cervical cancer. Estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp
4. Chuang LT, Temin S, Berek JS. 2016. Management and care of women with invasive cervical cancer. American Society of Clinical Oncology resource-stratified clinical practice guideline summary. J Oncol Pract 12:693-696. https://doi.org/10.1200/JOP.2016.014290; PMid:27328791
5. Jeronimo J, Castle PE, Temin S, et al: Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. J Glob Oncol. epub ahead of print on October 28, 2016.
6. de Sanjose S, Serrano B, Castellsague X, et al: Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries: A WHO/ICO HPV Information Centre report. Vaccine 30:D1-D83, vi. 2012 (suppl 4).
7. de Sanjose S, Wheeler CM, Quint WG et al. 2013. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomarkers Prev 22:1313-1318. https://doi.org/10.1158/1055-9965.EPI-13-0053; PMid:23632816 PMCid:PMC4306595
8. de Sanjose S, Quint WG, Alemany L et al. 2010. Human papillomavirus genotype attribution in invasive cervical cancer. A retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-1056. https://doi.org/10.1016/S1470-2045(10)70230-8
9. Centers for Disease Control and Prevention (CDC): FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Im- munization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59:626-629. 2010. PMid:20508593
10. Markowitz LE, Dunne EF, Saraiya M et al. 2007. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1-24. PMid:17380109
11. Markowitz LE, Dunne EF, Saraiya M et al. 2014. Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 63:1-30. PMid:25167164
12. Centers for Disease Control and Prevention (CDC): Recommendations on the use of quadrivalent human papillomavirus vaccine in males: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60:1705-1708. 2011. PMid:22189893
13. European Medicines Agency. Gardasil 9: EPAR – Summary for thepublic. http: //www.ema.europa.eu/ema/index.jsp? curl5pages/ medicines/ human/medicines/003852/human_med_001863.jsp&mid5WC0b01ac058001d124
14. Centers for Disease Control and Prevention. Provider information: Gardasil 9 vaccine information statements. http:// www. cdc.gov/vaccines/ hcp/vis/vis-statements/hpv-gardasil-9.html
15. Petrosky E, Bocchini JA Jr, Hariri S et al. 2015. Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 64:300-304. PMid:25811679
16. Wheeler CM, Castellsagué X, Garland SM et al. 2012. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:100-110. https://doi.org/10.1016/S1470-2045(11)70287-X
17. Schiller JT, Castellsague м X, Garland SM. 2012. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:F123-F138 (suppl 5).
18. Anderson BO, Shyyan R, Eniu A et al. 2006. Breast cancerin limited-resource countries. An overview of the Breast Health Global Initiative 2005 guidelines. Breast J 12:S3-S15 (suppl 1).
19. Horton S, Gauvreau CL. Cancer in low- and middle-income countries: An economic overview in Gelband H, Jha P, Sankaranarayanan R et al (eds). Cancer Disease Control Priorities (ed 3). Washington, DC, International Bank for Reconstruction and Development/World Bank. 2015. https://doi.org/10.1596/978-1-4648-0349-9_ch16
20. ADAPTE Collaboration. The ADAPTE process: Guidelineadaptation—Areso urcetoolkit(version2.0).http://www.g-i- n.net/document-store/working-groups-documents/adaptation/adapte-resource-toolkit-guideline-adaptation-2-0.pdf
21. Brouwers MC, Kho ME, Browman GP et al. 2010. AGREEII. Advancing guideline development, reporting and evaluation in health care. CMAJ 182:E839-E842. https://doi.org/10.1503/cmaj.090449; PMid:20603348 PMCid:PMC3001530
22. Shea BJ, Grimshaw JM, Wells GA et al. 2007. Development of AMSTAR. A measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 7:10. https://doi.org/10.1186/1471-2288-7-10; PMid:17302989 PMCid:PMC1810543
23. Shiffman RN, Michel G, Rosenfeld RM et al. 2012. Building better guidelines with BRIDGE-Wiz. Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc 19:94-101. https://doi.org/10.1136/amiajnl-2011-000172; PMid:21846779 PMCid:PMC3240753
24. World Health Organization: Meeting of the strategic advisory group of experts on immunization, April 2014: Con- clusions and recommendations. Wkly Epidemiol Rec 89:221-236. 2014. PMid:24864348
25. Couto E, Sæterdal I, Juvet LK et al. 2014. HPV catch-up vaccination of young women. A systematic review and meta- analysis. BMC Public Health 14:867. https://doi.org/10.1186/1471-2458-14-867; PMid:25149765 PMCid:PMC4159543
26. Public Health Agency of Canada National Advisory Committee on Immunization: Update on the recommended human papillomavirus (HPV) vaccine immunization schedule. https://www.canada.ca/en/public-health/services/publica- tions/healthy-living/update-recommended-human-papillomavirus-vaccine-immunization-schedule.html
27. Gross G, Becker N, Brockmeyer NH et al. 2014. Vaccination against HPV-associated neoplasias. Recommen- dations from the current S3 guideline of the HPV management forum of the Paul-Ehrlich Society—AWMF guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018. Geburtshilfe Frauenheilkd 74:233-241. https://doi.org/10.1055/s-0033-1360170
28. Australian Government Department of Health. The Australian Immunisation Handbook. ed 10: 4-6 Human papillomavirus. http: //www. immunise. health. gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home- ~handbook10part4~handbook10-4-6#4-6-7
29. Ben Hadj Yahia MB, Jouin-Bortolotti A, Dervaux B. 2015. Extending the human papillomavirus vaccination programme to include males in high-income countries. A systematic review of the cost-effectiveness studies. Clin Drug Investig 35:471-485. https://doi.org/10.1007/s40261-015-0308-4; PMid:26187455
30. Fesenfeld M, Hutubessy R, Jit M. 2013. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries. A systematic review. Vaccine 31:3786-3804. https://doi.org/10.1016/j.vaccine.2013.06.060; PMid:23830973
31. Armstrong EP. 2010. Prophylaxis of cervical cancer and related cervical disease. A review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm 16:217-230. https://doi.org/10.18553/jmcp.2010.16.3.217; PMid:20331326
32. Evidence based recommendations on human papillomavirus (HPV) vaccines schedules: Background paper for SAGE discussions. http: //www. who. int/ immunization/ sage/meetings/ 2014/april/1_HPV_Evidence_based_recommendations-WHO_with_ Appendices2_3.pdf?ua51
33. Centers for Disease Control and Prevention: CDC recommends only two HPV shots for younger adolescents. www. cancerview. ca/ Treatment And Support/GRCMain/GRCSAGE/GRCSAGESearch/
34. World Health Organization: Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 89:465-491. 2014. PMid:25346960
35. Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59:630-632. 2010. PMid:20508594
36. US National Library of Medicine: National Information Center on Health Services Research and Health Care Technology (NICHSR). https: //www. nlm.nih.gov/nichsr/hta101/ta10109.html
37. Sankaranarayanan R, Prabhu PR, Pawlita M et al. 2016. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India. A multicentre prospective cohort study. Lancet Oncol 17:67-77. https://doi.org/10.1016/S1470-2045(15)00414-3
38. Dobson SR, McNeil S, Dionne M et al. 2013. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs3 doses in young women: A randomized clinical trial. JAMA 309:1793-1802. https://doi.org/10.1001/jama.2013.1625; PMid:23632723
39. Krajden M, Cook D, Yu A et al. 2011. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 18:418-423. https://doi.org/10.1128/CVI.00489-10; PMid:21248158 PMCid:PMC3067374
40. Sankaranarayanan R. 2 vs 3 doses HPV vaccine schedule: Low- and middle-income countries. Presented at the Eurogin 2013 International Multidisciplinary Congress, Florence, Italy. 2013, November 3-6.
41. Institut National deSante мPubliqueduQue мbec: La vaccination despre м- adolescents contre les virusdu papillome humain (VPH) au Que мbec: Deux ou trois doses? http://www. inspq.qc.ca/pdf/publications/1683_VaccinPreA- doVPHQc_2ou3Doses.pdf
42. Romanowski B, Schwarz TF, Ferguson LM et al. 2014. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vaccin Immunother 10:1155-1165. https://doi.org/10.4161/hv.28022; PMid:24576907 PMCid:PMC4896558
43. Romanowski B, Schwarz TF, Ferguson LM et al. 2011. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule. Results from a randomized study. Hum Vaccin 7:1374-1386. https://doi.org/10.4161/hv.7.12.18322; PMid:22048171 PMCid:PMC3338934
44. GlaxoSmithKline: Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV vaccine 580299 when administered in healthy females aged 9 – 25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing. http://gsk-clinical study register. com/ files2/ebe3f40a-ef27-469c- 8874-35053b5a80d7
45. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Assessment report EMA/ 789820/2013: Cervarix. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/ human/ 000721/WC500160885.pdf
46. Esposito S, Birlutiu V, Jarcuska P et al. 2011. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: Results from a randomized study. Pediatr Infect Dis J 30:e49-e55. https://doi.org/10.1097/INF.0b013e318206c26e; PMid:21273939
47. Sankaranarayanan R: Evaluation of fewer than three doses of HPV vaccination in India. Presented at the WHO Consultation Meeting. Geneva, Switzerland. 2013.
48. Lazcano-Ponce E, Stanley M, Muñoz N et al. 2014. Overcoming barriers to HPV vaccination. Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 32:725-732. https://doi.org/10.1016/j.vaccine.2013.11.059; PMid:24355090
49. Puthanakit T, Huang LM, Chiu CH et al. 2016. Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years. J Infect Dis 214:525-536. https://doi.org/10.1093/infdis/jiw036; PMid:26908726 PMCid:PMC4957434
50. Garland SM, Stanley M, Brotherton J et al. 2016. IPVS policy statement on safety of HPV vaccines. Papillomavirus Res 2:9-10. https://doi.org/10.1016/j.pvr.2015.11.001; PMid:29074192
51. Husereau D, Drummond M, Petrou S et al. 2013. Consolidated Health Economic Reporting Standards (CHEERS): Ex- planation and elaboration—A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16:231-250. https://doi.org/10.1016/j.jval.2013.02.002; PMid:23538175
52. Brisson M, Benard E, Drolet M. 2016. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination. A systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Pub Health 1:e8-e17. https://doi.org/10.1016/S2468-2667(16)30001-9
53. Drolet M, Benard E, Boily MC et al. 2015. Population-level impact and herd effects following human papillomavirus vaccination programmes. A systematic review and meta-analysis. Lancet Infect Dis 15:565-580. https://doi.org/10.1016/S1473-3099(14)71073-4
54. Vichnin M, Bonanni P, Klein NP et al. 2015. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J 34:983-991. https://doi.org/10.1097/INF.0000000000000793; PMid:26107345
55. Garland SM, Ault KA, Gall SA et al. 2009. Pregnancy and infantoutcomesin the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: A combined analysis of five randomized controlled trials. Obstet Gynecol 114:1179-1188. https://doi.org/10.1097/AOG.0b013e3181c2ca21; PMid:19935017
56. Brotherton JM. 2013. Safety of the quadrivalent human papillomavirus vaccine. BMJ 347:631. https://doi.org/10.1136/bmj.f5631; PMid:24108153
57. Arnheim-Dahlstrо L, Pasternak B, Svanstrоm H et al. 2013. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort study. BMJ 347:906.
58. Global Advisory Committee on Vaccine Safety, 2-3 December 2015. Wkly Epidemiol Rec 91:21-31. 2016. PMid:26829825
59. Massad LS, Einstein MH, Huh WK et al. 2013. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 121:829-846. https://doi.org/10.1097/AOG.0b013e3182883a34; PMid:23635684
60. World Health Organization: WHO Guidelines for Screeningand Treatment of Precancerous Lesions for Cervical Cancer Prevention: WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland, World Health Organization. 2013.
61. Hildesheim A, Gonzalez P, Kreimer AR et al. 2016. Impact of human papillomavirus (HPV)16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol 215:212.e1-212.e15. https://doi.org/10.1016/j.ajog.2016.02.021; PMid:26892991 PMCid:PMC4967374
62. Hildesheim A, Wacholder S, Catteau G et al. 2014. Efficacy of the HPV-16/18 vaccine. Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32:5087-5097. https://doi.org/10.1016/j.vaccine.2014.06.038; PMid:25018097 PMCid:PMC4166498
63. Kang WD, Choi HS, Kim SM. 2013. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol 130:264-268. https://doi.org/10.1016/j.ygyno.2013.04.050; PMid:23623831
64. Joura EA, Garland SM, Paavonen J et al. 2012. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease. Retrospective pooled analysis of trial data. BMJ 344:e1401. https://doi.org/10.1136/bmj.e1401; PMid:22454089 PMCid:PMC3314184
65. European Medicines Agency: HPV vaccines: EMA confirms еvidence does not support that they cause CRPS or POTS.
67. Centersfor Disease Control and Prevention, Foodand Drug Administration:Vaccine Adverse Event Reporting System (VAERS). https://vaers.hhs.gov/index
68. Meites E, Kempe A and Markowitz LE. 2016. Use of a 2-dose schedule for human papillomavirus vaccination– updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 65:1405-1408. https://doi.org/10.15585/mmwr.mm6549a5; PMid:27977643
69. Garland SM, Subasinghe AK, Jayasinghe YL et al. 2015. HPV vaccination for victims of childhood sexualabuse. Lancet 386:1919-1920. https://doi.org/10.1016/S0140-6736(15)00757-6
70. Bailey HH, Chuang LT, duPont NC et al. 2016. American Society of Clinical Oncology Statement. Human papillomavirus vaccination for cancer prevention. J Clin Oncol 34:1803-1812. https://doi.org/10.1200/JCO.2016.67.2014; PMid:27069078
71. Dorell C, Yankey D, Kennedy A et al. 2013. Factors that influence parental vaccination decisions for adolescents, 13to17 years old. National Immunization Survey-Teen, 2010. Clin Pediatr (Phila) 52:162-170. https://doi.org/10.1177/0009922812468208; PMid:23221308
72. Gerend MA, Madkins K, Phillips G II et al. 2016. Predictors of human papillomavirus vaccination among young men who have sex with men. Sex Transm Dis 43:185-191. https://doi.org/10.1097/OLQ.0000000000000408; PMid:26859806 PMCid:PMC4748724
73. Gerend MA, Shepherd MA, Lustria ML et al. 2016. Predictors of provider recommendation for HPV vaccine among young adult men and women. Findings from a cross-sectional survey. Sex Transm Infect 92:104-107. https://doi.org/10.1136/sextrans-2015-052088; PMid:26297720
74. Rosenthal SL, Weiss TW, Zimet GD et al. 2011. Predictors of HPV vaccine uptake among women aged 19-26. Importance of a physician’s recommendation. Vaccine 29:890-895. https://doi.org/10.1016/j.vaccine.2009.12.063; PMid:20056186
75. Lehmann CE, Brady RC, Battley RO et al. 2016. Adolescent vaccination strategies: Interventions to increase coverage. Paediatr Drugs 18:273-285. https://doi.org/10.1007/s40272-016-0177-1; PMid:27146296
76. Bratic JS, Seyferth ER, Bocchini JAJr. 2016. Update on barriers to human papillomavirus vaccination and effective strategies to promote vaccine acceptance. Curr Opin Pediatr 28:407-412. https://doi.org/10.1097/MOP.0000000000000353; PMid:27093354
77. Lee Mortensen G, Adam M, Idtaleb L. 2015. Parental attitudes towards male human papillomavirus vaccination. A pan- European cross-sectional survey. BMC Public Health 15:624. https://doi.org/10.1186/s12889-015-1863-6; PMid:26152138 PMCid:PMC4495645
78. Gavi The Vaccine Alliance: Countries eligible for support. http: //www.gavi.org/support/apply/countries-eligible-for-support Kiatpongsan S,KimJJ:Costsandcost-effectivenessof9-valenthumanpapillomavirus (HPV) vaccinationin two East African countries. PLoS One 9:e106836. 2014.